Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open in the red
Fri, 21 Nov 09:30 am

The major Asian stock markets have opened the day on a mixed note with markets in Japan (down 0.5%) and Malaysia (down 0.5%) leading the losses. However, stock markets in Singapore (up 0.7%) and China (up 0.6%) were trading in the green. The Indian share markets have opened the day on a weak note. Barring capital goods and software, all sectoral indices have opened in the green with the stocks in the banking and healthcare sector leading the gains.

The Sensex today is down by around 16 points (0.1%), while the NSE-Nifty is down by about 1 point (0.01%). The mid cap and small cap stocks have opened in the green with BSE Mid Cap index and BSE Small Cap index up by around 0.2% and 0.4% respectively. The rupee is currently trading at Rs 61.85 to the US dollar.

Software stocks have opened the day on a mixed note with HCL Infosys and Info edge Ltd leading the gains. However, Infosys Ltd and Wipro Ltd were leading the losses. As per a leading financial daily, Tech Mahindra Ltd has acquired Virginia based Lightbridge Communications Corporation (LCC) for an enterprise value of approximately US$ 240 m. It is noteworthy that LCC is one-of-the world's largest independent global providers of network engineering services provider with more than 5000 employees in over fifty countries. The company's annual revenue stands at nearly US$ 400 m. The deal has been funded via internal accruals and the acquisition is likely to be completed by fourth quarter of FY15.

Indian Pharma stocks have opened mixed with Panacea Biotech Ltd and Cipla Ltd leading the gains. However, Ranbaxy Laboratories Ltd and Orchid Chemicals Ltd were leading the losses. As per a leading financial daily, Cipla Ltd has announced an agreement with Serum Institute of India (SII) for distribution of paediatric vaccines in Europe. As per the agreement, SII will develop and manufacture paediatric vaccines and Cipla will seek European Medicines Agency approval. Cipla will also market the products in Europe. The arrangement thus will allow Cipla to enter into the vaccines segment. It is noteworthy that in the past six months, Cipla has strengthened its presence in Europe and launched respiratory products such as Salmeterol/Fluticasone in Germany, Sweden, Czech Republic, Slovakia and Croatia. In July, it had signed an exclusive partnership with BioQuiddity regarding regional anaesthetic applications for post surgical pain management. As per Cipla's new strategy, the company is entering into various partnership deals to establish its front end presence in various markets

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Indian stock markets open in the red". Click here!

  

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market (Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


May 14, 2021 03:34 PM

S&P BSE SENSEX 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS